This report estimates the distribution of Myasthenia Gravis patients among Medicare Fee for Service, Medicare Advantage, Commercial, and Medicaid payer channels. We found 59% of myasthenia gravis patients are enrolled in Medicare and the remaining 41% are concentrated in the commercial market. The distribution of Medicare enrolled myasthenia gravis patients is evenly split between Medicare Advantage and traditional fee-for-service Medicare.

This report was commissioned by UCB, Inc.